KR102079919B1 - 단일-쇄 trail-수용체 작용제 단백질 - Google Patents

단일-쇄 trail-수용체 작용제 단백질 Download PDF

Info

Publication number
KR102079919B1
KR102079919B1 KR1020167032819A KR20167032819A KR102079919B1 KR 102079919 B1 KR102079919 B1 KR 102079919B1 KR 1020167032819 A KR1020167032819 A KR 1020167032819A KR 20167032819 A KR20167032819 A KR 20167032819A KR 102079919 B1 KR102079919 B1 KR 102079919B1
Authority
KR
South Korea
Prior art keywords
ser
gly
leu
lys
glu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020167032819A
Other languages
English (en)
Korean (ko)
Other versions
KR20170012257A (ko
Inventor
올리버 힐
크리슈티안 기페르스
마이놀프 티만
프릿츠 지. 뷰캐넌
대런 시. 필립스
수잔 이. 랩
Original Assignee
애브비 인코포레이티드
아포게닉스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 애브비 인코포레이티드, 아포게닉스 아게 filed Critical 애브비 인코포레이티드
Publication of KR20170012257A publication Critical patent/KR20170012257A/ko
Application granted granted Critical
Publication of KR102079919B1 publication Critical patent/KR102079919B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
KR1020167032819A 2014-04-23 2015-04-23 단일-쇄 trail-수용체 작용제 단백질 Expired - Fee Related KR102079919B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461983152P 2014-04-23 2014-04-23
US61/983,152 2014-04-23
PCT/US2015/027270 WO2015164588A1 (en) 2014-04-23 2015-04-23 Single-chain trail-receptor agonist proteins

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020197035100A Division KR20190135546A (ko) 2014-04-23 2015-04-23 단일-쇄 trail-수용체 작용제 단백질

Publications (2)

Publication Number Publication Date
KR20170012257A KR20170012257A (ko) 2017-02-02
KR102079919B1 true KR102079919B1 (ko) 2020-02-24

Family

ID=53055121

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020167032819A Expired - Fee Related KR102079919B1 (ko) 2014-04-23 2015-04-23 단일-쇄 trail-수용체 작용제 단백질
KR1020197035100A Ceased KR20190135546A (ko) 2014-04-23 2015-04-23 단일-쇄 trail-수용체 작용제 단백질

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020197035100A Ceased KR20190135546A (ko) 2014-04-23 2015-04-23 단일-쇄 trail-수용체 작용제 단백질

Country Status (38)

Country Link
US (5) US9908927B2 (enExample)
EP (2) EP3366699A1 (enExample)
JP (2) JP6523331B2 (enExample)
KR (2) KR102079919B1 (enExample)
CN (2) CN106459221B (enExample)
AR (1) AR100168A1 (enExample)
AU (3) AU2015249649B2 (enExample)
BR (1) BR112016024515B1 (enExample)
CA (2) CA2946402C (enExample)
CL (1) CL2016002683A1 (enExample)
CR (1) CR20160516A (enExample)
CY (1) CY1120281T1 (enExample)
DK (1) DK3134430T3 (enExample)
DO (1) DOP2016000284A (enExample)
EC (1) ECSP16089579A (enExample)
ES (1) ES2672368T3 (enExample)
HR (1) HRP20180950T1 (enExample)
HU (1) HUE038914T2 (enExample)
IL (2) IL248244B (enExample)
LT (1) LT3134430T (enExample)
MA (2) MA45069A (enExample)
MX (2) MX2016013858A (enExample)
MY (1) MY181986A (enExample)
NO (1) NO2776305T3 (enExample)
PE (1) PE20170299A1 (enExample)
PH (2) PH12020500377A1 (enExample)
PL (1) PL3134430T3 (enExample)
PT (1) PT3134430T (enExample)
RS (1) RS57153B1 (enExample)
RU (1) RU2699285C2 (enExample)
SG (3) SG10202111785VA (enExample)
SI (1) SI3134430T1 (enExample)
SM (1) SMT201800286T1 (enExample)
TR (1) TR201806912T4 (enExample)
TW (2) TWI683825B (enExample)
UA (1) UA118286C2 (enExample)
UY (1) UY36095A (enExample)
WO (1) WO2015164588A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2745801C2 (ru) * 2015-05-04 2021-04-01 Аподжиникс Аг Одноцепочечные белки-агонисты рецептора cd40
EP3364995B1 (en) 2015-10-23 2021-08-04 Apogenix AG Single-chain cd27-receptor agonist proteins
AU2016341402B2 (en) * 2015-10-23 2020-08-27 Apogenix Ag Single-chain GITR-receptor agonist proteins
JP6873119B2 (ja) * 2015-10-23 2021-05-19 アポジェニックス アーゲー 一本鎖ｌｉｇｈｔ受容体アゴニストタンパク質
WO2017102010A1 (en) * 2015-12-17 2017-06-22 Biontech Rna Pharmaceuticals Gmbh Novel cytokine fusion proteins
CN109153711B (zh) * 2016-03-01 2022-04-26 伊利诺伊大学理事会 具有降低的l-谷氨酰胺酶活性和增强的稳定性的l-天冬酰胺酶变体和融合蛋白
US20190077870A1 (en) * 2016-03-16 2019-03-14 Merrimack Pharmaceuticals, Inc. Engineered trail for cancer therapy
US10501744B2 (en) 2016-05-04 2019-12-10 Indiana University Research And Technology Corporation Presentation of bioactive proteins
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
CA3027380A1 (en) * 2016-06-13 2017-12-21 Merrimack Pharmaceuticals, Inc. Methods for selecting and treating patients with a trail-based therapeutic or death receptor agonist
EP3360898A1 (en) 2017-02-14 2018-08-15 Boehringer Ingelheim International GmbH Bispecific anti-tnf-related apoptosis-inducing ligand receptor 2 and anti-cadherin 17 binding molecules for the treatment of cancer
AU2018313253B2 (en) * 2017-08-11 2024-09-26 The Board Of Trustees Of The University Of Illinois Truncated guinea pig L-asparaginase variants and methods of use
WO2019178438A1 (en) 2018-03-15 2019-09-19 Abbvie Inc. Abbv-621 in combination with anti-cancer agents for the treatment of cancer
TW202002952A (zh) 2018-03-15 2020-01-16 美商艾伯維有限公司 用於治療胰臟癌之abbv-621與抗癌劑之組合
US20230212260A1 (en) 2020-05-15 2023-07-06 Apogenix Ag Multi-specific immune modulators
CA3217894A1 (en) 2021-05-28 2022-12-01 Gernot Stuhler Recombinant proteinaceous binding molecules
WO2023088876A1 (en) 2021-11-16 2023-05-25 Apogenix Ag Multi-specific immune modulators

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010033315A1 (en) 2008-09-22 2010-03-25 Amgen Inc. Method of treatment
WO2013092983A2 (en) 2011-12-23 2013-06-27 Innate Pharma Enzymatic conjugation of polypeptides

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001025277A1 (en) 1999-10-07 2001-04-12 Maxygen Aps Single-chain antagonist polypeptides
DE19963859A1 (de) 1999-12-30 2001-07-12 Apotech Res & Dev Ltd Bi- oder Oligomer eines Di-, Tri-, Quattro- oder Pentamers von rekombinanten Fusionsproteinen
CA2314199A1 (en) 2000-07-21 2002-01-21 Robert Simoneau C-chip
MXPA03005036A (es) 2000-12-07 2003-09-05 Lilly Co Eli Proteinas de fusion glp-1.
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
AU2003234274A1 (en) * 2002-04-26 2003-11-10 California Institute Of Technology D1-1 nucleic acids, polypeptides and related methods
DE102004014983A1 (de) 2004-03-26 2005-10-20 Univ Stuttgart Rekombinante Polypeptide der Mitglieder der TNF Ligandenfamilie und deren Verwendung
US20060188498A1 (en) * 2005-02-18 2006-08-24 Genentech, Inc. Methods of using death receptor agonists and EGFR inhibitors
WO2006109301A2 (en) 2005-04-15 2006-10-19 Rappaport Family Institute For Research In The Medical Sciences Molecules and methods of using same for treating mcp-1/ccr2 associated diseases
US8008443B2 (en) 2005-04-26 2011-08-30 Medimmune, Llc Modulation of antibody effector function by hinge domain engineering
EP1894940A1 (en) 2006-08-28 2008-03-05 Apogenix GmbH TNF superfamily fusion proteins
CA2692802C (en) 2007-07-10 2017-05-30 Oliver Hill Tnf superfamily collectin fusion proteins
BRPI0913406A2 (pt) 2008-06-03 2018-01-09 Abbott Lab imunoglobulinas de domínio variável duplo e usos das mesmas
HRP20150425T1 (hr) 2008-07-21 2015-06-05 Apogenix Gmbh Tnf sf jednolanäśane molekule
CA2739663A1 (en) * 2008-10-10 2010-05-15 Anaphore, Inc. Polypeptides that bind trail-r1 and trail-r2
WO2010078966A1 (en) 2009-01-09 2010-07-15 Apogenix Gmbh Fusion proteins forming trimers
CA2750533A1 (en) * 2009-01-23 2010-07-29 Biogen Idec Ma Inc. Stabilized fc polypeptides with reduced effector function and methods of use
WO2011076781A1 (en) 2009-12-22 2011-06-30 Novartis Ag Tetravalent cd47-antibody constant region fusion protein for use in therapy
JP2013523179A (ja) * 2010-04-13 2013-06-17 メディミューン，エルエルシー フィブロネクチンタイプｉｉｉドメインに基づく多量体足場
SG11201500134QA (en) 2012-07-18 2015-03-30 Apogenix Gmbh Composition comprising a mixture of cd95-fc isoforms

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010033315A1 (en) 2008-09-22 2010-03-25 Amgen Inc. Method of treatment
WO2013092983A2 (en) 2011-12-23 2013-06-27 Innate Pharma Enzymatic conjugation of polypeptides

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Cytokins & Growth Factor Reviews, Vol.25(2):185-193 (2014. 4. 1.)
Molecular Cancer Therapeutics, Vol.12(12):2735-2747 (2013. 12. 1.)

Also Published As

Publication number Publication date
RU2699285C2 (ru) 2019-09-04
AR100168A1 (es) 2016-09-14
BR112016024515A2 (pt) 2017-10-10
SG10202111785VA (en) 2021-12-30
PE20170299A1 (es) 2017-05-06
ECSP16089579A (es) 2018-05-31
PT3134430T (pt) 2018-04-20
NO2776305T3 (enExample) 2018-01-27
CN106459221B (zh) 2020-09-01
JP6523331B2 (ja) 2019-05-29
EP3366699A1 (en) 2018-08-29
RU2016145608A3 (enExample) 2018-12-26
RS57153B1 (sr) 2018-07-31
IL272612A (en) 2020-03-31
PH12020500377A1 (en) 2022-11-14
HRP20180950T1 (hr) 2018-08-10
BR112016024515B1 (pt) 2020-03-31
AU2018271369B2 (en) 2020-01-02
CN111718424A (zh) 2020-09-29
US20210040178A1 (en) 2021-02-11
CL2016002683A1 (es) 2017-07-07
TWI747178B (zh) 2021-11-21
US20250145688A1 (en) 2025-05-08
PH12016502079A1 (en) 2016-12-19
UY36095A (es) 2015-10-30
SI3134430T1 (en) 2018-05-31
DOP2016000284A (es) 2017-02-15
KR20170012257A (ko) 2017-02-02
NZ725476A (en) 2023-09-29
JP2017513503A (ja) 2017-06-01
JP2019162114A (ja) 2019-09-26
EP3134430B1 (en) 2018-03-21
JP6714751B2 (ja) 2020-06-24
CA2946402A1 (en) 2015-10-29
CA2946402C (en) 2023-02-28
US20180222962A1 (en) 2018-08-09
MA45069A (fr) 2019-04-03
AU2015249649A1 (en) 2016-11-10
DK3134430T3 (en) 2018-05-22
EP3134430A1 (en) 2017-03-01
RU2016145608A (ru) 2018-05-28
TWI683825B (zh) 2020-02-01
US20150337027A1 (en) 2015-11-26
UA118286C2 (uk) 2018-12-26
US9908927B2 (en) 2018-03-06
ES2672368T3 (es) 2018-06-14
KR20190135546A (ko) 2019-12-06
MX2016013858A (es) 2017-08-02
SG10201806465TA (en) 2018-08-30
US20240174731A1 (en) 2024-05-30
TW201620928A (zh) 2016-06-16
CR20160516A (es) 2017-05-10
AU2015249649B2 (en) 2018-10-04
SG11201608767XA (en) 2016-11-29
IL248244B (en) 2020-03-31
LT3134430T (lt) 2018-05-10
CA3184067A1 (en) 2015-10-29
CN106459221A (zh) 2017-02-22
PH12016502079B1 (en) 2016-12-19
CY1120281T1 (el) 2019-07-10
PL3134430T3 (pl) 2018-08-31
MY181986A (en) 2021-01-18
MX2019013587A (es) 2020-01-13
AU2020202247A1 (en) 2020-04-23
TR201806912T4 (tr) 2018-06-21
SMT201800286T1 (it) 2018-07-17
TW202024123A (zh) 2020-07-01
HUE038914T2 (hu) 2018-12-28
IL248244A0 (en) 2016-11-30
MA39770A (fr) 2015-10-29
AU2018271369A1 (en) 2018-12-20
WO2015164588A1 (en) 2015-10-29

Similar Documents

Publication Publication Date Title
US20240174731A1 (en) Single-chain trail-receptor agonist proteins
US20210246190A1 (en) Single-chain cd137-receptor agonist proteins
US10683332B2 (en) Single-chain light receptor agonist proteins
US11149075B2 (en) Single-chain glucocorticoid-induced tumor necrosis factor receptor (GITR) receptor agonist proteins
US20180230196A1 (en) Single-chain ox40-receptor agonist proteins
HK1260151A1 (en) Single-chain trail-receptor agonist proteins
HK1235072A1 (en) Single-chain trail-receptor agonist proteins
HK1235072B (en) Single-chain trail-receptor agonist proteins
NZ725476B2 (en) Single-chain trail-receptor agonist proteins

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20240218

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20240218